View Item 

Show simple item record

A model for in situ plan of care for a critically unstable pediatric patient following I‐131 MIBG infusion
dc.contributor.authorFlori, Heidi Rosanna
dc.contributor.authorMwenesi, Rama
dc.contributor.authorScott, Annette
dc.contributor.authorConrad, Christina Marie
dc.contributor.authorQuinn, Justin Andrew
dc.contributor.authorOstwani, Waseem
dc.contributor.authorFischer, Karl William
dc.contributor.authorYanik, Gregory Anthony
dc.date.accessioned2020-10-01T23:30:58Z
dc.date.availableWITHHELD_14_MONTHS
dc.date.available2020-10-01T23:30:58Z
dc.date.issued2020-11
dc.identifier.citationFlori, Heidi Rosanna; Mwenesi, Rama; Scott, Annette; Conrad, Christina Marie; Quinn, Justin Andrew; Ostwani, Waseem; Fischer, Karl William; Yanik, Gregory Anthony (2020). "A model for in situ plan of care for a critically unstable pediatric patient following I‐131 MIBG infusion." Pediatric Blood & Cancer 67(11): n/a-n/a.
dc.identifier.issn1545-5009
dc.identifier.issn1545-5017
dc.identifier.urihttps://hdl.handle.net/2027.42/162761
dc.description.abstractRecent clinical trials have moved iodine‐131 (I‐131) metaiodobenzylguanidine (MIBG) therapy into frontline management of high‐risk neuroblastoma. With this expansion, it is reasonable to anticipate the need for intensive care level resuscitations. Radiation exposure remains the greatest risk to health care professionals managing these patients. We combined shock simulation scenario data with actual radiation dosimetry data to create a care model allowing for aggressive, prolonged in situ resuscitation of a critically ill pediatric patient after I‐131 MIBG administration. This model will maintain a critical care provider’s radiation level below 10% of the annual occupational dose limit (5 mSv, 500 mrem) per patient managed.
dc.publisherNRC Library
dc.publisherWiley Periodicals, Inc.
dc.titleA model for in situ plan of care for a critically unstable pediatric patient following I‐131 MIBG infusion
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPediatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/162761/2/pbc28665.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/162761/1/pbc28665_am.pdfen_US
dc.identifier.doi10.1002/pbc.28665
dc.identifier.sourcePediatric Blood & Cancer
dc.identifier.citedreferenceU.S. NRC. Occupational Dose Limits for Adults‐10 CFR 20.1201. NRC Library; 56 FR 23396, May 21, 1991, updated 2007.
dc.identifier.citedreferenceMatthay K, Villablanca J, Seeger R, et al. Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bome marrow transplant and 12‐cis‐retinoic acid. N Engl J Med. 1999; 341: 1165 ‐ 1173.
dc.identifier.citedreferenceMatthay K, George R, Yu A. Promising therapeutic targets in neuroblastoma. Clin Cancer Res. 2012; 18 ( 10 ): 2740 ‐ 2753.
dc.identifier.citedreferenceMatthay K, Huberty J, Hattner R, et al. Efficacy and safety of 131‐metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med. 1991; 35: 244 ‐ 247.
dc.identifier.citedreferenceMatthay K, Panina C, Huberty J, et al. Correlation of tumor and whole body dosimetry with tumor response and toxicity in refractory neuroblastoma treated wtih (131)I‐MIBG. J Nucl Med. 2001; 42: 1713 ‐ 1721.
dc.identifier.citedreferenceHoward J, Maris J, Kersun L, et al. Tumor response adn toxicity with multiple infusions of high dose 131I‐MIBG for refractory neuroblastoma. Pediatric Blood Cancer. 2005; 44: 233 ‐ 239.
dc.identifier.citedreferenceSharp S, Trout A, DeWeiss B, Gelfand M. MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics. 2016; 36: 258 ‐ 278.
dc.identifier.citedreferenceDubois S, Allen S, Bent M, et al. Phase 1/II study of (131)I‐MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. Br J Cancer. 2015; 112: 644 ‐ 649.
dc.identifier.citedreferenceShusterman S, Grant F, Lorenzen W, et al. Iodine‐131‐labeled meta‐iodobenzylguanidine therapy of children witih neuroblastoma: program planning and initial experience. Semin Nucl Med. 2011; 41: 354 ‐ 363.
dc.identifier.citedreferenceTurpin B, Morris V, Lemen L, et al. Minimizing nuclear medicine technologist radiation exposure during 131 I‐MIBG therapy. Health Phys. 2013; 104: S43 ‐ S46.
dc.identifier.citedreferenceValentin J. International Commission on Radiological Protection 1997‐2001. Ann ICRP. 2000; 30 (1): ISSN 0146‐6453.
dc.identifier.citedreferenceU.S. NRC. Dose Equivalent to an Embryo/Fetus‐10 CFR 20.1208. NRC Library; 56 FR 23396, May 21, 1991, as amended at 63 FR 39482, July 23, 1998.
dc.identifier.citedreferenceU.S. NRC 10 CFR 35.75. Release of Individuals Containing Unsealed Byproduct Material or Implants Containing Byproduct Material. Updated 72 FR 45151, Aug. 13, 2007.
dc.identifier.citedreferenceCougnenc O, Defachelles A, Carpentier P, et al. High dose 131I‐MIBG therapies in children” feasibility, patient dosimetry and radiation exposure to workers and family caregivers. Radiat Prot Dosimetry. 2017; 173 ( 4 ): 395 ‐ 404.
dc.identifier.citedreferenceWillegaignon J, Crema K, Oliviera N, et al. Pediatric 131I‐MIBG therapy for neuroblastoma: whole body 131I‐MIBG clearance, radiation doses to patients, family caregivers, medical staff and radiation safety measures. Clin Nucl Med. 2018; 43 ( 8 ): 572 ‐ 578.
dc.identifier.citedreferenceMarkelewicz R, Lorenzen W, Shusterman S, Grant F, Fahey F, ST T. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131 I‐metaiodobenzylguanidine therapy. Clin Nucl Med. 2013; 38 ( 8 ): 604 ‐ 607.
dc.identifier.citedreferenceLee J, Wu R, Wong T, et al. Extended sedation with continuous midazolam or dexmedetomidine infusion for young children receiving 131 I‐MIBG radiopharmaceutical therapy for advanced neuroblastoma. Pediatr Blood Cancer. 2016; 63 ( 3 ): 417 ‐ 418.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
pbc28665_am.pdf
Size:
532.0KB
Format:
PDF
View/Open
Name:
pbc28665.pdf
Size:
416.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.